Moreover, defactinib (VS-6063), a FAK and proline-rich tyrosine kinase 2 (PYK2) dual inhibitor, is currently undergoing multiple clinical trials in NSCLC and mesothelioma (16). Here, PTK2B is linked to mesothelioma.